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The occurrence of Langerhans cell histiocytosis (LCH) and another malignancy in the same patient is 
infrequent but has been recognized.  The genetic changes that could be responsible for LCH and/or 
concomitant leukemia development are obscure.  To the best of our knowledge,  this is the ﬁrst 
description of constitutional maternally derived inv (9) (p12; q13) in an LCH patient,  and also of the 
development of common ALL Ph＋ after LCH diagnosis and therapy.  The potential signiﬁcance of 
these ﬁndings [inv (9)＋LCH＋ALL Ph＋] and their mutual relationship are unknown.  Therefore,  
cooperative studies of large numbers of patients are needed to identify the common risk factors,  if 
any.
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angerhans cell histiocytosis (LCH) is both the 
result of clonal proliferation of Langerhans 
cells (LC) and the immunologic consequence of 
increased cellular activation.  It may be associated 
with acute lymphoblastic leukemia,  malignant lym-
phoma or other malignant solid tumors.  Malignancy 
can occur before,  after,  or concurrently with the 
diagnosis of LCH.  The LCH-Malignancy Study Group 
initiated the registry of patients in whom this associa-
tion occurred synchronously or asynchronously.  Haupt 
and coworkers reported that by May 2002,  92 
patients were registered,  and of 71 pediatric LCH 
patients,  27 suﬀered from solid tumors,  21 from 
AnLL,  17 from ALL and 6 from lymphoma.  In 20 
patients,  malignancy occurred between 7 months and 
10 years after LCH.
Case Report
　 The genetic changes that could be responsible for 
LCH and/or concomitant leukemia development are 
obscure.  Here,  we describe a 4-year-old boy who 
developed acute lymphoblastic leukemia (ALL) with 
Ph＋ cells in the bone marrow 2 months after sys-
temic LCH went into remission due to treatment with 
etoposide (VP-16).  The boy was seen at our clinic at 
the age of 9 months because he suﬀered from intermit-
tent fever.  Clinical check-up showed leukocytosis with 
78×109/L WBC,  liver and spleen enlargement,  
migrating joint pain and swelling,  enlargement of 
lymph nodes and migrating skin rash.  Bone marrow 
smears demonstrated LC histiocytic inﬁltration.  
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Electron microscope analysis conﬁrmed the presence 
of Birbeck granules.  The boy was karyotyped because 
of his unusual phenotype,  predominantly of the face,  
and his anamnesis of 2 operations,  one at the age of 2 
years for bilateral inguinal hernia and the other at the 
age of 3 years for Ductus Bottali persistens.  He 
presented phenotypically with microcephaly,  hyperte-
lorism,  bilateral epicanthal folds,  low set ears,  low 
bridged nose,  upward slanted palpebral ﬁssures,  high 
palate,  low set umbilicus,  4 ﬁnger line on both hands,  
dysplastic toes,  and bilateral cryptorchidism.  His 
karyotype was: 46, XY,  inv (9) (p12; q13) (mat).  His 
mother was a carrier of 46,  XX,  inv (9) (p12; q13).
　 The boy was treated with etoposide (VP-16) at 
200mg/m2 for 3 consecutive days (one cycle) for 15 
cycles with intervals of 3 weeks between cycles,  fol-
lowed by maintenance therapy with interferon,  after 
which he achieved complete remission.  However,  
ALL occurred 2 months after LCH remission (2 years 
and 2 months after the ﬁrst etoposide treatment),  and 
it was treated as high-risk leukemia with the standard 
BFM protocol.  The malignant disease was conﬁrmed 
by immunophenotyping and by cytological analysis of 
bone marrow.  The karyotype displayed the Philadel-
phia translocation 9; 22 (q34; q11.2) on one chromo-
some 9 and inv (9) (p12; q13) (mat) on the other.  The 
latter is a constitutional variation inherited from the 
subjectʼs mother (Fig.  1).
　 However,  it turned out that ALL was resistant to 
the BFM treatment,  and the boy died in the ﬁrst early 
relapse.  In the motherʼs next pregnancy,  prenatal 
diagnosis was performed,  and a healthy boy without 
per inv (9) was born.  Both parents gave their consent 
to release patient/maternal medical information.
Discussion
　 The reasons that the malignancy occurs in patients 
with LCH are still unknown.  Two main possibilities 
exist.  Either the therapy for LCH on one side or a 
genetic predisposition or a susceptibility to the facili-
tated development of pathogenic molecular abnormali-
ties on the other side promotes tumor development.  
Regarding the ﬁrst possibility,  it should be noted that 
the therapy for LCH patients is still controversial.  
Therefore,  the question arises as to whether etopo-
side may induce the development of malignancy.  So 
far,  only a few studies have suggested that LCH 
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Fig. 1　 Karyotype 46, XY,  inv (9) (11p; 13q),  t (9; 22) (q34; q11) Ph＋ of a boy in which acute lymphoblastic leukemia developed 2 
months after systemic Langerhans cell histiocytosis (LCH) reached remission.  The karyotype displays Philadelphia translocation 9; 22 
(q43; q11.2) on one chromosome 9 (left chromosome of the 9th pair ― short arrow),  and inv (9) (p12; q13) (mat) (right chromosome of the 
9th pair ― dashed arrow) on the other.  The latter is a constitutional variation inherited from the mother.
Chromosome pairs 1,  2,  3,  4,  5 and XY (ﬁrst row); 6,  7,  8,  9,  10,  11,  12 (second row); 13,  14,  15,  16,  17,  18 (third row); and 19,  
20,  21,  22 (fourth row).  The small arrow on chromosome pair 22 indicates a deletion in 22q11 [t (9; 22) (q34; q11) Ph＋].
therapy can induce tumor development,  and most of 
them involved only a small number of patients [1-4].  
Although it seems to us that the ﬁrst possible reason 
for malignancy development,  i.e.  the therapy for LCH 
on one side,  may explain the ALL development in our 
patient,  some other observations should also be kept 
in mind.  In all papers describing tumor development 
after LCH treatment,  a much longer period (i.e.,  
longer than in our case) was needed for the tumor 
development to occur [1].  In addition,  there have 
been only sporadic observations that ALL develops 
secondary to LCH [5]; it is usually observed to pre-
cede LCH [6,  7].  The most common secondary 
malignancy described in the literature is myeloid leu-
kemia,  whose development is usually ascribed to 
medical treatment for LCH [2-4].
　 The second possibility (genetic predisposition or the 
susceptibility to facilitated development of pathogenic 
molecular abnormalities) might also be operative in our 
case.  The inherited pericentric inversion of the het-
erochromatic region of chromosome 9 inv (9) (p12; q13) 
has been regarded as a normal constitutional karyo-
type variant with no clinically signiﬁcant conse-
quences.  However,  some reports have shown an 
association between inherited inv (9) and a predisposi-
tion to develop solid tumors,  acute lymphoblastic 
leukemia and myeloblastic leukemias [8-11].  Moreover,  
even acquired inv (9),  although rare,  could also be 
associated with the development of acute myeloid leu-
kemia and essential thrombocythemia [12,  13].  
Therefore,  it is possible that inv (9) individuals have 
either latent impaired hematopoiesis or that the inher-
ited derangement of chromosome 9 [inv (9)] contrib-
utes to the genetic change in the second allele 9 
[(9; 22)] translocation.
　 In sum,  we have identiﬁed,  for the ﬁrst time,  an 
inherited inv (9) (p12; q13) in an LCH patient as well 
as the development of acute lymphoblastic leukemia 
after LCH diagnosis and therapy.  The potential sig-
niﬁcance of these ﬁndings [inv (9)/LCH/ALL] and 
their mutual relationship is unknown to us.  There-
fore,  this is a call to all clinicians who manage LCH 
patients to also perform cytogenetic studies so that the 
incidence of inherited inv (9) can be accurately esti-
mated and eventually related more precisely to the 
development of LCH with accompanying leukemia.
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